Patents by Inventor Mark E. Zak
Mark E. Zak has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20220389020Abstract: A compound of Formula I, enantiomers, diasteriomers, tautomers or pharmaceutically acceptable salts thereof, wherein R1, R2 and R3 are defined herein, are useful as inhibitors of one or more Janus kinases. A pharmaceutical composition that includes a compound of Formula I and a pharmaceutically acceptable carrier, adjuvant or vehicle, and methods of treating or lessening the severity of a disease or condition responsive to the inhibition of a Janus kinase activity in a patient are disclosed.Type: ApplicationFiled: January 14, 2022Publication date: December 8, 2022Applicant: Genentech, Inc.Inventors: Paul Gibbons, Emily Hanan, Wendy Liu, Joseph P. Lyssikatos, Steven R. Magnuson, Rohan Mendonca, Richard Pastor, Thomas E. Rawson, Michael Siu, Mark E. Zak, Aihe Zhou, Bing-Yan Zhu, Christopher Hurley
-
Publication number: 20200002345Abstract: A compound of Formula I, enantiomers, diasteriomers, tautomers or pharmaceutically acceptable salts thereof, wherein R1, R2 and R3 are defined herein, are useful as inhibitors of one or more Janus kinases. A pharmaceutical composition that includes a compound of Formula I and a pharmaceutically acceptable carrier, adjuvant or vehicle, and methods of treating or lessening the severity of a disease or condition responsive to the inhibition of a Janus kinase activity in a patient are disclosed.Type: ApplicationFiled: September 5, 2019Publication date: January 2, 2020Applicant: Genentech, Inc.Inventors: Paul Gibbons, Emily Hanan, Wendy Liu, Joseph P. Lyssikatos, Steven R. Magnuson, Rohan Mendonca, Richard Pastor, Thomas E. Rawson, Michael Siu, Mark E. Zak, Aihe Zhou, Bing-Yan Zhu, Christopher Hurley
-
Publication number: 20190233441Abstract: Compounds of Formula 0, Formula I and Formula II and methods of use as Janus kinase inhibitors are described herein.Type: ApplicationFiled: April 2, 2019Publication date: August 1, 2019Applicant: Genentech, Inc.Inventors: Nicholas C. Ray, Yun-Xing Cheng, Christine Edwards, Simon C. Goodacre, Wei Li, Snahel Patel, Matthew W. Cartwright, Mohammed Sajad, Po-wai Yuen, Mark E. Zak
-
Publication number: 20180298033Abstract: Compounds of Formula 0, Formula I and Formula II and methods of use as Janus kinase inhibitors are described herein.Type: ApplicationFiled: December 14, 2017Publication date: October 18, 2018Applicant: Genentech, Inc.Inventors: Nicholas C. Ray, Yun-Xing Cheng, Christine Edwards, Simon C. Goodacre, Wei Li, Snahel Patel, Matthew W. Cartwright, Mohammed Sajad, Po-wai Yuen, Mark E. Zak
-
Patent number: 9873709Abstract: Compounds of Formula 0, Formula I and Formula II and methods of use as Janus kinase inhibitors are described herein.Type: GrantFiled: April 27, 2017Date of Patent: January 23, 2018Assignee: Genentech, Inc.Inventors: Nicholas C. Ray, Yun-Xing Cheng, Christine Edwards, Simon C. Goodacre, Wei Li, Snahel Patel, Matthew W. Cartwright, Mohammed Sajad, Po-wai Yuen, Mark E. Zak
-
Publication number: 20170283424Abstract: A compound of Formula I, enantiomers, diasteriomers, tautomers or pharmaceutically acceptable salts thereof, wherein R1, R2 and R3 are defined herein, are useful as inhibitors of one or more Janus kinases. A pharmaceutical composition that includes a compound of Formula I and a pharmaceutically acceptable carrier, adjuvant or vehicle, and methods of treating or lessening the severity of a disease or condition responsive to the inhibition of a Janus kinase activity in a patient are disclosed.Type: ApplicationFiled: June 20, 2017Publication date: October 5, 2017Applicant: Genentech, Inc.Inventors: Paul Gibbons, Emily Hanan, Wendy Liu, Joseph P. Lyssikatos, Steven R. Magnuson, Rohan Mendonca, Richard Pastor, Thomas E. Rawson, Michael Siu, Mark E. Zak, Aihe Zhou, Bing-Yan Zhu, Christopher Hurley
-
Publication number: 20170226132Abstract: Compounds of Formula 0, Formula I and Formula II and methods of use as Janus kinase inhibitors are described herein.Type: ApplicationFiled: April 27, 2017Publication date: August 10, 2017Applicant: Genentech, Inc.Inventors: Nicholas C. Ray, Yun-Xing Cheng, Christine Edwards, Simon C. Goodacre, Wei Li, Snahel Patel, Matthew W. Cartwright, Mohammed Sajad, Po-wai Yuen, Mark E. Zak
-
Publication number: 20160185780Abstract: Compounds of Formula 0, Formula I and Formula II and methods of use as Janus kinase inhibitors are described herein.Type: ApplicationFiled: March 4, 2016Publication date: June 30, 2016Applicant: Genentech, Inc.Inventors: Nicholas C. RAY, Yun-Xing CHENG, Christine EDWARDS, Simon C. GOODACRE, Wei LI, Snahel PATEL, Matthew W. CARTWRIGHT, Mohammed SAJAD, Po-wai YUEN, Mark E. ZAK
-
Publication number: 20150152117Abstract: A compound of Formula I, enantiomers, diasteriomers, tautomers or pharmaceutically acceptable salts thereof, wherein R1, R2 and R3 are defined herein, are useful as inhibitors of one or more Janus kinases. A pharmaceutical composition that includes a compound of Formula I and a pharmaceutically acceptable carrier, adjuvant or vehicle, and methods of treating or lessening the severity of a disease or condition responsive to the inhibition of a Janus kinase activity in a patient are disclosed.Type: ApplicationFiled: February 6, 2015Publication date: June 4, 2015Applicant: Genentech, Inc.Inventors: Paul Gibbons, Emily Hanan, Wendy Liu, Joseph P. Lyssikatos, Steven R. Magnuson, Rohan Mendonca, Richard Pastor, Thomas E. Rawson, Michael Siu, Mark E. Zak, Aihe Zhou, Bing-Yan Zhu
-
Publication number: 20120309765Abstract: The invention relates to a method of inhibiting abnormal cell growth or treating a hyperproliferative disorder in a mammal comprising administering to said mammal a therapeutically effective amount of an imidazopyridine of formula I with anti-hyperproliferative activity.Type: ApplicationFiled: August 15, 2012Publication date: December 6, 2012Applicant: Genentech, Inc.Inventors: Stephen Price, Robert Heald, Wendy Lee, Mark E. Zak, Joanne Frances Mary Hewitt
-
Patent number: 8288408Abstract: The invention relates to a method of inhibiting abnormal cell growth or treating a hyperproliferative disorder in a mammal comprising administering to said mammal a therapeutically effective amount of an imidazopyridine of formula I with anti-hyperproliferative activity.Type: GrantFiled: March 7, 2011Date of Patent: October 16, 2012Assignee: Genentech, Inc.Inventors: Stephen Price, Robert Heald, Wendy Lee, Mark E. Zak, Joanne Frances Mary Hewitt
-
Publication number: 20110158990Abstract: The invention relates to a method of inhibiting abnormal cell growth or treating a hyperproliferative disorder in a mammal comprising administering to said mammal a therapeutically effective amount of an imidazopyridine of formula I with anti-hyperproliferative activity.Type: ApplicationFiled: March 7, 2011Publication date: June 30, 2011Applicant: Genentech, Inc.Inventors: Stephen Price, Robert Heald, Wendy Lee, Mark E. Zak, Joanne Frances Mary Hewitt
-
Patent number: 7923456Abstract: The invention relates to imidazopyridines of formula I with anti-cancer and/or anti-inflammatory activity and more specifically to imidazopyridines which inhibit MEK kinase activity. The invention provides compositions and methods useful for inhibiting abnormal cell growth or treating a hyperproliferative disorder, or treating an inflammatory disease in a mammal. The invention also relates to methods of using the compounds for in vitro, in situ, and in vivo diagnosis or treatment of mammalian cells, or associated pathological conditions.Type: GrantFiled: April 29, 2009Date of Patent: April 12, 2011Assignee: Genentech, Inc.Inventors: Stephen Price, Robert Heald, Wendy Lee, Mark E. Zak, Joanne Frances Mary Hewitt
-
Publication number: 20100004269Abstract: The invention relates to imidazopyridines of formula I with anti-cancer and/or anti-inflammatory activity and more specifically to imidazopyridines which inhibit MEK kinase activity. The invention provides compositions and methods useful for inhibiting abnormal cell growth or treating a hyperproliferative disorder, or treating an inflammatory disease in a mammal. The invention also relates to methods of using the compounds for in vitro, in situ, and in vivo diagnosis or treatment of mammalian cells, or associated pathological conditions.Type: ApplicationFiled: April 29, 2009Publication date: January 7, 2010Applicant: Genentech, Inc.Inventors: Stephen Price, Robert Heald, Wendy Lee, Mark E. Zak, Joanne Frances Mary Hewitt
